Revvity has acquired companies in sectors with high-growth potential, such as cell and gene therapies, and precision medicine, among other sectors. The company has strengthened its debt position ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

WALTHAM, Mass., February 20, 2025--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity ...

Revvity, Inc. has a 12-month low of $97.32 and a 12-month high of $129.50. The stock has a market capitalization of $13.67 billion, a P/E ratio of 50.83, a P/E/G ratio of 3.97 and a beta of 1.03.

Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity’s rights under its agreements ...

Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days. At Revvity, “impossible” is inspiration ...

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor ...

In its fourth quarter 2024 investor letter, Bretton Fund emphasized stocks such as Revvity, Inc. (NYSE:RVTY). Revvity, Inc. (NYSE:RVTY) offers health sciences solutions, technologies, and services.